Ambu has been facing headwinds on the stock exchange in recent days, and Head of Equity Research at Carnegie Investment Bank Niels Granholm-Leth has identified several potential factors as to why.
”It seems as if there might have been some exaggerated fears that the company might have to bring in new capital to continue its current strategy. It’s far from certain that the company’s new leadership will continue the previous capital-demanding course,” assesses Granholm-Leth says.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Genmab to submit cancer candidate epcoritamab to the FDA before year-end
The US Food and Drug Administration will receive a marketing authorization application from Genmab and partner Abbvie in the second half of this year.
Novo Nordisk denied general conditional reimbursement for Wegovy in Denmark – again
The Danish Medicines Agency has been told for the second time that the price of the obesity drug is not in line with the effect it provides.
Bavarian Nordic is working with EMA on monkeypox vaccine label expansion
Bavarian Nordic’s smallpox vaccine Imvanex has previously been used off-label to protect close contacts from monkeypox in several countries. The Danish vaccine firm is now working with the EMA to expand the label in an ”accelerated process.”
Coloplast's climate goals approved by international initiative
The Science Based Targets initiative has approved Coloplast’s carbon emission reduction goals.
Top news from MedWatch this week
Miss anything?
Project Managers keep all of us healthy 
KLIFO is looking for a Project Director for our office in Denmark or Germany or Sweden 
Associate, Regulatory Affairs Life Cycle Management 
Chair of the Board 
Clinical Project Leader/ Sr. Clinical Trial Manager – make a difference and join our mission to bring our IL-22 lead program to patients 
Device Associate Director/Senior Project Leader 
Senior Scientist for Analytical Development 
Scientific Writer 
Director Regulatory Affairs 
Senior Teaching Fellow for the BioMedical Design Novo Nordisk Foundation Fellowship Program 
Global Product Manager - ENT 
Principal Scientist – Pharmacology 
Nordic Medical Advisor